StreetAlpha.app
Home › Stocks › LXEO

Lexeo Therapeutics, Inc. (LXEO)

$2.96
▲ +0.34%
LAST CLOSE · NOV 20

Lexeo Therapeutics develops gene therapies that aim to treat inherited heart diseases in patients with genetic cardiomyopathies. It last closed at $2.96 on Nov 20, up 0.34% on the day. The next earnings report for LXEO is expected around Mon, Mar 29, 2027, after the close. For the quarter ended Sep 2026, LXEO reported EPS of -$0.43. Over its last 8 reports the stock moved an average of 10.8% the session after earnings. Over the last 12 months LXEO insiders bought $0 of stock on the open market and sold $739K, according to SEC Form 4 filings.

AI Auto Pilots
Is LXEO in one of our AI portfolios?
Five AI traders run real portfolios in the open, with every decision logged. Create a free account to see if they hold LXEO.

Key Stats

Last 12 months
Results
Net income
−$105.3M
EPS (diluted)
−$1.13
Free cash flow
−$87.7M
Valuation
Market cap
$245.1M
82.8M shares
P/E
–
No P/E while losing money
Dividend yield
None
No dividend in 12 months
Balance sheet
Cash & equivalents
$90.2M
At Sep 30
Shareholder equity
$216.7M
Shares outstanding
82.8M
At Nov 12
Fiscal year endsDecember
ExchangeNasdaq
Financials history
FY2022: −$59.3M−$59.3MFY2022FY2023: −$66.4M−$66.4MFY2023FY2024: −$98.3M−$98.3MFY2024FY2025: −$100.0M−$100.0MFY2025

From LXEO's SEC filings, latest 10-Q for the period ending Sep 30, 2026 (filed Nov 16). Last 12 months adds up the four latest quarters.

Next report
Mar 29
Estimated date · After the close
Reported EPS
-$0.43
Quarter ended Sep 2026
Year ago EPS
-$0.33
Same quarter last year
Revenue
—
Last reported quarter
Estimates and implied move
Consensus forecasts and the move options price in
EPS by quarter (GAAP)
Dec 2024: -$0.78Dec '24Mar 2025: -$0.99Mar '25Jun 2025: -$0.60Jun '25Sep 2025: -$0.33Sep '25Dec 2025: -$0.14Dec '25Mar 2026: -$0.25Mar '26Jun 2026: -$0.30Jun '26Sep 2026: -$0.43Sep '26Latest -$0.43
Revenue by quarter
Not enough quarters on file yet.
How LXEO moved after its last 8 reports
Average move the session after a report ±10.8%
Nov 16, 2026Time not announced+12.5%
Aug 12, 2026Time not announced+1.9%
May 11, 2026Time not announced+5.0%
Mar 30, 2026After the close+8.9%
Oct 17, 2025After the close−3.8%
Aug 14, 2025Time not announced+1.5%
May 12, 2025Time not announced−2.2%
Mar 24, 2025Time not announced+50.9%
Close to close, the session after each report, adjusted for splits. Past moves are no guide to the next one.
StreetAlpha's call on LXEOStart your 7 day free trial to see StreetAlpha's call before the report, with the options flow, dark pool, history and technical scores behind it.Sign up freeSign in

Analyst Ratings & Price Targets

Analyst Ratings →
AI Starter and AI Pro
Full analyst coverage on LXEO
  • Every upgrade, downgrade and initiation as it happens
  • Every price target change, raised or cut
  • Consensus rating with the average, high and low targets
  • Each firm's full rating history on LXEO

Technical Analysis

LXEO · as of the Nov 20 close · updated each morning
Downtrend

The stock is 2% below its 20 day and 9% below its 50 day average. It is 65% below its 200 day average, so the longer trend is down. Momentum is improving (RSI 47). The nearest support is the Pivot S1 at $2.82, and the nearest resistance the 20 day average at $3.00.

Short trendBearish
Long trendBearish
MomentumImproving
StretchNormal
VolatilityHigh, 12.6%/day
Key levels
$10.9952 week high+271.3%
$4.88200 day average+64.9%
$3.97100 day average+34.1%
$3.2250 day average+8.8%
$3.17Pivot R1+7.1%
$3.12Swing high (Oct 22)+5.4%
$3.03Pivot+2.4%
$3.0020 day average+1.4%
$2.96Last close
$2.82Pivot S1−4.7%
$2.70Swing low (Nov 6)−8.8%
$2.5552 week low−13.9%
Indicators
RSI (14)46.89Middle of its rangeNeutral
MACD-0.07Above its signal lineBullish
Stochastic15.8Near the bottom of its rangeOversold
ADX (14)22.1Weak trend
Williams %R-83.8Oversold below −80, overbought above −20Oversold
CCI (20)-1.0Oversold below −100, overbought above 100Neutral
Rate of change+2.4%Change over 10 sessionsBullish
ATR (14)$0.37Typical daily range, 12.6% of price
MA 10Below
MA 20Below
MA 50Below
MA 100Below
MA 200Below
What happened before, for LXEO

What happened before

See how LXEO did after each of today's signals in the past: how often it was higher 10 sessions later, and the typical move, next to its usual record. Free with an account.

November seasonalityHow LXEO usually does this month. See Seasonality

Calculated from daily prices after each close. Signals describe the chart, not where the stock will go. Past patterns often fail. Not investment advice.

AI Day Trader
Watch Claude day trade the open, live.
Every session it trades SPY, QQQ, IWM and two daily stock picks, with each call logged before the move.

Seasonality

How LXEO has done in each calendar month: the average and median return, how often each month finished higher, and every year since 2023.

Loading…

See the stocks that usually rise in November →

Whale Options Flow

90D
Whale options flow for LXEOHow many large options trades hit LXEO, the bullish and bearish split, and every trade with strike, premium and expiry are shown to AI Starter and AI Pro members.Sign up freeSign in

See today’s whale options flow across the market →

LXEO Institutional Ownership

Full report →
Fund sentiment · Q3 2026
Strongly bullish
Strongly bearishNeutralStrongly bullish
  • ▲81 buying vs 54 selling
  • ▲Held by funds +2.6 pts
  • ▲Funds holding +11
  • ▲Superinvestors: 4 added, 0 cut
  • ●Put/call not meaningful
Q4 '24Q1 '25Q2 '25Q3 '25Q4 '25Q1 '26Q2 '26Q3 '26
Funds holdingHeld by funds %
Q3 2026This quarterLast quarterChange
Funds holding153142+7.7%
In funds' top 10110.0%
Held by funds110.8%108.2%+2.6 pts
New / increased30 / 5127 / 58−4.7%
Reduced / sold out36 / 1839 / 23−12.9%
Put/call ratio–––
Top holders, biggest buyers and sellers, 8 quarters of charts and this season's filings so far.See LXEO institutional ownership →

From SEC Form 13F filings for Sep 30, 2026. What the filings show, not a forecast: positions can be up to 45 days old and leave out short sales.

LXEO Insider Trading

All filings →
Insider trading · 12 months
Insiders are only selling
Bought$00 buys · 0 insiders
Sold$739K15 sales · 4 insiders
42% of the selling was under pre-arranged trading plans.
2026-02 sold $84K2026-04 sold $313K2026-05 sold $24K2026-07 sold $257K2026-08 sold $43K2026-11 sold $18KDecMarJunSep
BoughtSoldlast 12 months
Trade dateInsiderTypeSharesPriceValue
Nov 17Richard Nolan TownsendCEOSale3,295$3.26$11K
Nov 17Jose Manuel OteroCOOSale1,285$3.26$4K
Nov 17Louis Edward TamayoCFOSale1,007$3.26$3K
Aug 18Richard Nolan TownsendCEOSale3,345$4.95$17K
Aug 18Jose Manuel OteroCOOSale1,304$4.96$6K
Aug 18Louis Edward TamayoCFOSale4,117$4.91$20K
Every insider buy and sale for LXEO over 2 years, with a link to each SEC filing. AI Pro members can get an alert the moment an insider trades.See LXEO insider trades →

From SEC Form 4 filings by LXEO's officers, directors and 10% owners. Open market buys and sales only; option exercises, gifts, awards and tax withholding are left out. Not investment advice.

AI Auto Pilots

Paper trading

StreetAlpha runs autonomous AI traders powered by Anthropic's Claude. Each one reads options flow, dark pool prints, insider filings, sentiment, macro signals and technicals, then makes its own trading decisions in a paper portfolio. Every decision is logged and every trade is tracked, so you can see whether LXEO is in one of them and how their past LXEO trades turned out.

LXEO in the AI portfolios
Loading…

LXEO News Tone and Price

Loading…

Macro & Market News

All StreetAlpha news →

StreetAlpha hasn't covered LXEO in an article yet. Here's the latest on the wider market.

LXEO in the news

About Lexeo Therapeutics

Lexeo Therapeutics is a biotechnology company based in New York that develops gene therapies for inherited heart diseases. Its candidates are designed to deliver working copies of disease-linked genes to heart muscle cells. The lead programs target Friedreich ataxia cardiomyopathy and arrhythmogenic cardiomyopathy caused by PKP2 gene mutations, and the company is also developing candidates for other genetic heart conditions. Its target patients have genetic heart diseases with few or no approved treatments.

Headquarters
New York, NY